Commentary - Journal of Cancer Immunology (2021) Volume 3, Issue 2
Cervical Cancer Prevalence in sub-Saharan Africa and HPV Vaccination Policy: A Public Health Grand Challenge?
School of Health Policy and Management, Faculty of Health, York University, 4700 Keele Street, Toronto, ON, Canada
- *Corresponding Author:
- Eric Asempah
Received date: February 22, 2021; Accepted date: March 29, 2021
Citation: Asempah E. Cervical Cancer Prevalence in sub-Saharan Africa and HPV Vaccination Policy: A Public Health Grand
Challenge?. J Cancer Immunol. 2021; 3(2): 87-97.
Copyright: © 2021 Asempah E. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Cervical cancer cases in low-income countries (LICs) are on the rise, whereas the reverse is true for high-income countries (HICs). With
sub-Saharan Africa carrying the highest burden of cervical cancer cases and deaths globally, demand for governments in the region to
act proactively in addressing the situation is a clarion call. Unfortunately, this is not the case as cervical cancer receives low attention
from governments in the sub-Saharan region compared to other disease areas. Cervical cancer research interest and prevention policy
has also been found to be low among researchers in sub-Saharan Africa. This paper comments on the sub-Saharan cervical cancer and
HPV vaccination policy narrative and clarifies the imperative for action; in particular, given the resulting morbidity and mortality due
to cervical cancer is preventable. The paper emphasizes scientists’ call to promote health and the need for governments to consider
research and researchers’ opinion when designing policy to eradicate cervical cancer. The prevalence of the disease and the mortality
rate in the sub-Saharan region represent a public health grand challenge. Engaging relevant stakeholders to actively collaborate in
reducing and eventually eliminating the disease is encouraged.
Cervical cancer, HPV vaccination, Policy, Priority, sub-Saharan Africa
“Women are not dying because of diseases we cannot treat. They are dying because societies have yet to make the decision that their lives are worth saving.”
Dr. Mahmoud Fathala
Past President, International Federation of
Gynaecology and Obstetrics (FIGO)
One life lost is one too much to ignore, but when it comes to cervical cancer, it is reported that “(a) total of 740 women die each day” from the disease globally . Cervical cancer is a leading (4th) cause of cancer among females and affects over half a million globally in a year [2-5]. In sub-Saharan Africa, it is the leading cause of cancer
death among women [5,6].
The 2020 assessment by GLOBOCAN indicates that there were 604,000 new cases and 342,000 deaths from cervical cancer globally . It has been estimated that about 372.2 million females under the age of 15 years are at risk of cervical cancer in Africa, of which 119,284 are diagnosed every year, and 81,687 die from the disease (68.5% mortality rate) . The World Health Organization
(WHO) has estimated that as resource-poor regions like
sub-Saharan Africa struggle in managing the disease,
“without an effective intervention, global cervical cancer
deaths will increase to 460,000 by 2040” .
Continuing evidence shows that regions with low Human Development Index (HDI) score experience disproportionately high levels of cervical cancer incidence and mortality rate [5,9,10]. This supports the high prevalence of cervical cancer cases and mortality in sub- Saharan Africa where the HDI has been historically low with high Human Poverty Indices (HPI). While this is the case, the high prevalence of the disease in low-income countries (LICs) has been attributed to the lack of political will, cultural issues, and poor health systems that cannot identify and treat precancerous lesions promptly [11-13].
Comparatively, high-income countries (HICs) have recorded a lower incidence rate of cervical cancer [14,15] attributed to policy decisions and actions such as cervical cancer screening to detect and treat at an early stage, and the introduction of nationwide HPV vaccination programs [14,16,17]. For instance, a woman in the U.S. has a 70%
chance of surviving cervical cancer while the survival
chances for a woman in sub-Saharan African is 21% .
The high prevalence of cervical cancer in LICs delineates
a case of global health inequity [19,20]. Gossa and Fetters
have referred to this inequity as an ethical problem
that expresses an “epidemiological tragedy” needing
prioritization from policymakers and international donors
. According to the WHO, most people who are actively
involved in sexual activity will be infected with HPV at
some point in their lives . This presents a societal
health risk that requires government policy actions to
avert needless suffering and risk of death for women due
to HPV-associated cervical cancer.
HPV-Associated Cervical Cancer and
With over 200 different strains of HPV, about 15 strains have been identified as high-risk strains that cause various types of cancers (e.g., cervix, vulva, vagina, anus, penis, and oropharynx) [22,23]. Of these strains, the 16 and 18 strains have been identified as an etiological cause of cervical cancer [24-26]. Whereas HPV infections are themselves “asymptomatic and transient” with nearly 70% clearing in the first year of infection and nearly 91% clearing in the second year of infection, high-risk strains (16 and 18) parasitically persist longer than normal . The persistence of HPV infections over several years can lead to “grade 2 or 3 cervical intraepithelial neoplasia (CIN) and cervical cancer” (ibid).
In a meta-analysis of 192 studies that tested over one million women globally for cervical HPV infection, Bruni and colleagues showed that the adjusted HPV prevalence among women with normal cytological findings was estimated to be 11.7% per 100,000 women (95% confidence interval (CI): 11.6–11.7%) . The study shows that sub- Saharan African regions reported the highest adjusted prevalence of 24% at 95% confidence intervals (ibid). Sadly, most of these deaths occur among women who live in poverty .
On June 8, 2006, the U.S Food and Drug Administration approved Merck’s HPV antiviral quadrivalent (6,11,16 and 18) vaccine, Gardasil, “for females 9-26 years of age to protect against cervical, vulvar, and vaginal cancers caused by (HPV)” . The latest version, Gardasil-9, provides wider protection against 9 different strains of HPV types (6,11,16,18,31,33,45,52 and 58) [29,30]. HPV Bivalent (16 and 18) Vaccine, Recombinant (a.k.a. Cervarix), “for use in females 10 through 25” years manufactured by GSK received approval from the U.S. FDA on October 15, 2009 [31-33]. Gardasil and Cervarix have been assessed by the
WHO and endorsed as safe and efficacious for globally use . Currently, the Chinese biotechnology company,
Xiamen Innovax Biotech, has also introduced a bivalent
HPV vaccine, Cecolin, which has been approved by the
China National Medical Products Administration. Cecolin
is currently under review by the WHO for prequalification
with a timeline to complete the review by the end of 2021
The HPV vaccination regimen is designed on a 3-dose program to be given at 0, 2, and 6-month time-point. Dobson and colleagues in a randomized clinical trial study of HPV vaccine in younger adolescents however showed that a 2-dose schedule for girls was “possible” . While this is the case, a cohort study of 10,204 women in Alberta, Canada concluded that women who received full vaccination (> 2 doses) had a lower adjusted odds ratio (OR) of 0.72 (95% confidence interval [CI] 0.63– 0.82) . Those who had 2 dose HPV vaccination had an adjusted OR of 0.50 (95% CI 0.30–0.85) (ibid). The study suggests that the 3-dose regime provided greater protection and lowers the risk of cervical cancer among women. Even though the 3-dose schedule may provide lower risk, a cost-effectiveness assessment conducted by Laprise and colleagues have shown that a 2-dose schedule that provides a protection period of at least 10 years is cost effective . The authors concluded vaccination with a 2-dose schedule that provides “longer than 30 years” is better than a 3-dose schedule (ibid). While some countries maintain the 3-dose schedule, the 2-dose schedule proves to be equally potent and economically cost-effective.
HPV Vaccination Programs in sub- Saharan African Regions
Even though cervical cancer remains a life-threatening disease globally, vaccination against high-risk HPV strains (16 and 18) has prophylactically led to the prevention of the disease. While many HICs have explored and incorporated HPV vaccination in their healthcare programs (e.g., national immunization) besides other traditional interventions such as screening, this is not the case in most resource-poor settings – especially in sub-Saharan Africa where case incidence and mortality rates are high (see Table 1). This is further exacerbated by inadequate vaccine access in LICs where universal access to primary healthcare is often limited or unavailable , precluding opportunities for cervical cancer screening as a secondary prevention strategy that occurs in HICs . For example, as of 2019, only nine sub-Saharan African States have been identified to have a Nationwide HPV vaccination program (see Table 1). According to HPV Information Center, three countries have announced the introduction of HPV vaccination program while 18 have a pilot project in place to introduce the vaccination nationwide (see Table 1). 19 countries however have no HPV vaccination program in place (see Table 1).
Challenges to HPV Vaccination in sub- Saharan African Regions
The availability of HPV vaccines in HICs has been successful mostly through responsive government priority setting [42-44], which is not the case in resource-poor settings like sub-Saharan Africa (Table 2). For example, in a comprehensive epidemiological review of cervical cancer disease burden in sub-Saharan Africa, the authors noted that the extent of the cervical cancer problem has been “under-recognized and underprioritized”  in comparison to other high mortality diseases such as HIV ⁄ AIDS, tuberculosis and malaria.
Even though some African nations developed initiatives and programs to promote awareness and introduce HPV vaccines to their citizens, program and policy inertia due to various factors that hinder HPV vaccine uptake and coverage has made this a challenge. In a recent study, the authors reported that only 1-2% of women between the age of 10-20 received HPV vaccination in the region . A driving factor to the problem to the low HPV vaccination problem has been attributed to the lack of resources to finance and deploy the vaccines in the region . While the Global Alliance for Vaccine Immunization (GAVI) provides support to some LICs to enable access to HPV vaccines, other countries are unable to do so due to their inability to meet certain pre-qualification requirements . This directly expands the inequity that exists in
HPV vaccination among countries, especially in the sub-
Saharan African region.
While acknowledging the contributions of sub-Saharan African scholars in the cervical cancer prevention and control narrative, there is a subtle passiveness as expressed in the number of articles coming from the region and the leadership role taken in joint publishing .
This disengages an active participation space for scholarships that could inform policymakers on interventional strategies. Cervical cancer prevention and control in sub-Saharan Africa also seems to be of low priority in the region due to possibly competing disease areas or other governmental interests than cervical cancer prevention and control. For example, in Ghana, where cervical cancer is the most common cancer among women, it is the least prioritized for intervention by governments [50,51]. According to a report by the International Agency for Research on Cancer (IARC), 8.57 million women from the ages of 15 years and above are at risk of cervical cancer in Ghana . Not surprisingly, cases of cervical cancer continue to rise in Ghana [23,50-53]. While this is the case, citizens’ knowledge remains low about cervical cancer, HPV, and/or HPV vaccination. A cross-sectional study of 285 adolescents in Ghana shows that about 91.2% of the participants had not heard of HPV and 95.4% had not heard of HPV vaccination, for example . Previous studies reported similar findings in Ghana, indicating low public education on cervical cancer, its prevention, and/ or control [50,55,56]. In a systematic review estimating the knowledge and awareness of the HPV vaccine and acceptability to vaccinate in sub-Saharan Africa, the authors concluded that “there is an urgent need for more education to inform the public about HPV, HPV vaccine, and cervical cancer, particularly to key demographics, (adolescents, parents and healthcare professionals)” .
The International Covenant on Economic, Social, and Cultural Rights (ICESCR) highlights health as a fundamental human right to the enjoyment of the highest attainable standard of physical and mental health. Most sub-Saharan African countries are signatories to the ICESCR, through which they commit to protecting citizens’ right to health as a fundamental human right. Sub- Saharan governments are thus obligated to take measures to protect the health of their citizens, in this case, women against cervical cancer.
Cervical cancer not only threatens women’s health but also contributes to worsening the socio-economic challenges in the sub-Saharan region due to lost human capital. It thus presents a public health grand challenge that is imperative to address by engaging all stakeholders, including scientists, and particularly governments in the sub-Saharan region, working together to reduce and eventually eliminate the disease in alignment with the WHO’s global strategy to eliminate cervical cancer by 2030 .
I wish to thank Prof. Mary E. Wiktorowicz and Prof. A.M.
Viens for their reviews and suggestions.
Conflicts of Interest
No conflict of interest is declared for this work.
No funding was received for this work.
- Small Jr W, Bacon MA, Bajaj A, Chuang LT, Fisher BJ,
Harkenrider MM, et al. Cervical cancer: a global health
crisis. Cancer. 2017 Jul 1;123(13):2404-12.
- De Martel C, Ferlay J, Franceschi S, Vignat J, Bray F,
Forman D, et al. Global burden of cancers attributable to
infections in 2008: a review and synthetic analysis. The
Lancet Oncology. 2012 Jun 1;13(6):607-615.
- Clendinen C, Zhang Y, Warburton RN, Light DW.
Manufacturing costs of HPV vaccines for developing
countries. Vaccine. 2016 Nov 21;34(48):5984-9.
- Plummer M, de Martel C, Vignat J, Ferlay J, Bray F,
Franceschi S. Global burden of cancers attributable to
infections in 2012: a synthetic analysis. The Lancet Global
Health. 2016 Sep 1;4(9):e609-16.
- H. Sung, J. Ferlay, R.L. Siegel, M. Laversanne, I.
Soerjomataram, A. Jemal, F. Bray, Global cancer statistics
2020: GLOBOCAN estimates of incidence and mortality
worldwide for 36 cancers in 185 countries, CA: A Cancer
Journal for Clinicians. (2021).
- Jedy-Agba E, Joko WY, Liu B, Buziba NG, Borok
M, Korir A, et al. Trends in cervical cancer incidence in
sub-Saharan Africa. British Journal of Cancer. 2020 Jul;
- Bruni L, Albero G, Serrano B, Mena M, Gómez D,
Muñoz J, et al. ICO/IARC information centre on HPV and
cancer (HPV information centre). Human papillomavirus
and related diseases in the world. Summary Report. 2019
Jun 17; 17.
- WHO, Cervical Cancer, World Health ORganization. (2020). https://www.afro.who.int/health-topics/cervicalcancer (accessed September 26, 2020).
- Singh GK, Azuine RE, Siahpush M. Global inequalities
in cervical cancer incidence and mortality are linked
to deprivation, low socioeconomic status, and human
development. International Journal of MCH and AIDS.
- Mansori K, Khazaei S, Shadmani FK, Hanis SM,
Jenabi E, Soheylizad M, et al. Global inequalities in cervical
cancer incidence and mortality. Middle East Journal of
- Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco
G, Mayrand MH, et al. Overview of human papillomavirusbased
and other novel options for cervical cancer screening
in developed and developing countries. Vaccine. 2008 Aug
- Kidwell Drake J, Hutchings JE, Elias CJ.
Making evidence work for communities: the role of
nongovernmental organizations in translating science
to programs. Journal of Women’s Health. 2010 Nov
- Wigle J, Coast E, Watson-Jones D. Human
papillomavirus (HPV) vaccine implementation in
low and middle-income countries (LMICs): health
system experiences and prospects. Vaccine. 2013 Aug
- De Vuyst H, Alemany L, Lacey C, Chibwesha CJ,
Sahasrabuddhe V, Banura C, et al. The burden of human
papillomavirus infections and related diseases in subsaharan
Africa. Vaccine. 2013 Dec 29;31:F32-46.
- Black E, Richmond R. Prevention of cervical cancer
in sub-Saharan Africa: The advantages and challenges of
HPV vaccination. Vaccines. 2018 Sep;6(3):61.
- Bonanni P, Levi M, Latham NB, Bechini A, Tiscione
E, Lai P, et al. An overview on the implementation of
HPV vaccination in Europe. Human Vaccines. 2011 Jan
- Bonanni P, Bechini A, Donato R, Capei R, Sacco C, Levi
M, et al. Human papilloma virus vaccination: impact and
recommendations across the world. Therapeutic Advances
in Vaccines. 2015 Jan;3(1):3-12.
- Parry J. Controversial new vaccine to prevent cervical
cancer. Bulletin of the World Health Organization.
- Agosti JM, Goldie SJ. Introducing HPV vaccine in
developing countries—key challenges and issues. New
England Journal of Medicine. 2007 May 10;356(19):1908-
- Lancet T. The right to cervical cancer services in
- Gossa W, Fetters MD. How should cervical cancer
prevention be improved in LMICs?. AMA Journal of
Ethics. 2020 Feb 1;22(2):126-34.
- Chen Z, Schiffman M, Herrero R, DeSalle R, Anastos
K, Segondy M, et al. Classification and evolution of human
papillomavirus genome variants: Alpha-5 (HPV26, 51, 69,
82), Alpha-6 (HPV30, 53, 56, 66), Alpha-11 (HPV34, 73),
Alpha-13 (HPV54) and Alpha-3 (HPV61). Virology. 2018
- Awua AK, Severini A, Wiredu EK, Afari EA, Zubach VA,
Adanu RM. Self-Collected Specimens Revealed a Higher
Vaccine-and Non-Vaccine-Type Human Papillomavirus
Prevalences in a Cross-Sectional Study in Akuse. Advances in Preventive Medicine. 2020 Jan 22;2020.
- Crosbie EJ, Einstein MH, Franceschi S, Kitchener HC.
Human papillomavirus and cervical cancer. The Lancet.
2013 Sep 7;382(9895):889-99.
- Castellsagué X. Natural history and epidemiology of
HPV infection and cervical cancer. Gynecologic Oncology.
2008 Sep 1;110(3):S4-7.
- Zimmerman RK. Ethical analysis of HPV vaccine
policy options. Vaccine. 2006 May 29;24(22):4812-20.
- Bruni L, Diaz M, Castellsagué M, Ferrer E, Bosch FX,
de Sanjosé S. Cervical human papillomavirus prevalence
in 5 continents: meta-analysis of 1 million women with
normal cytological findings. Journal of Infectious Diseases.
2010 Dec 15;202(12):1789-99.
- U.S. FDA, Gardasil Vaccine Safety, Gardasil Vaccine Safety. (2009). https://www.fda.gov/vaccines-bloodbiologics/safety-availability-biologics/gardasil-vaccinesafety (accessed March 15, 2020).
- Centers for Disease Control and Prevention (CDC.
FDA licensure of quadrivalent human papillomavirus
vaccine (HPV4, Gardasil) for use in males and guidance
from the Advisory Committee on Immunization Practices
(ACIP). MMWR. Morbidity and mortality weekly report.
2010 May 28;59(20):630-632.
- Kirby T. FDA approves new upgraded Gardasil 9. The
Lancet Oncology. 2015 Feb 1;16(2):e56.
- DA, Cervarix, FDA. (2019). http://www.fda.gov/vaccines-blood-biologics/vaccines/cervarix (accessed March 15, 2020).
- Einstein MH, Baron M, Levin MJ, Chatterjee
A, Edwards RP, Zepp F, et al. Comparison of the
immunogenicity and safety of Cervarix™ and Gardasil®
human papillomavirus (HPV) cervical cancer vaccines in
healthy women aged 18–45 years. Human vaccines. 2009
- Szarewski A. HPV vaccine: Cervarix. Expert Opinion
on Biological Therapy. 2010 Mar 1; 10(3):477-87.
- WHO, Immunization, Vaccines and Biologicals, WHO. (2021). https://www.who.int/immunization/hpv/vaccines/en/.
- GAVI, Gavi-supported HPV vaccines profiles to
support country decision making, (2020). https://www.gavi.org/sites/default/files/2020-09/Gavi-HPVvaccines-September-2020-1.pdf (accessed March 5, 2021).
- Dobson SR, McNeil S, Dionne M, Dawar M, Ogilvie G, Krajden M, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. Jama. 2013 May 1;309(17):1793-802.
- Kim J, Bell C, Sun M, Kliewer G, Xu L, McInerney
M, et al. Effect of human papillomavirus vaccination
on cervical cancer screening in Alberta. Cmaj. 2016 Sep
- Laprise JF, Drolet M, Boily MC, Jit M, Sauvageau
C, Franco EL, et al. Comparing the cost-effectiveness of
two-and three-dose schedules of human papillomavirus
vaccination: a transmission-dynamic modelling study.
Vaccine. 2014 Oct 7;32(44):5845-53.
- WHO, Human papillomavirus (HPV) and cervical cancer, (2019). https://www.who.int/news-room/factsheets/detail/human-papillomavirus-(hpv)-and-cervicalcancer (accessed March 11, 2020).
- Iwu CJ, Jaca A, Abdullahi LH, Ngcobo NJ, Wiysonge
CS. A scoping review of interventions for vaccine stock
management in primary health-care facilities. Human
Vaccines & Immunotherapeutics. 2019 May 22.
- Ebell MH, Thai TN, Royalty KJ. Cancer screening
recommendations: an international comparison of high
income countries. Public Health Reviews. 2018 Dec;
- Steben M. Do you approve of spending $300 million
on HPV vaccination?: yes. Canadian Family Physician.
2008 Feb 1; 54(2):174-6.
- Brotherton JM, Zuber PL, Bloem PJ. Primary
prevention of HPV through vaccination: update on the
current global status. Current Obstetrics and Gynecology
Reports. 2016 Sep;5(3):210-24.
- Shapiro GK, Guichon J, Kelaher M. Canadian schoolbased
HPV vaccine programs and policy considerations.
Vaccine. 2017 Oct 9;35(42):5700-7.
- Louie KS, De Sanjose S, Mayaud P. Epidemiology and
prevention of human papillomavirus and cervical cancer
in sub-Saharan Africa: a comprehensive review. Tropical
Medicine & International Health. 2009 Oct;14(10):1287-
- Zhuang RY, Goyal H, Xu HG. Gender-neutral HPV
vaccination in Africa. The Lancet Global Health. 2019 May
- Dutta T, Meyerson B, Agley J. African cervical cancer
prevention and control plans: A scoping review. Journal of
Cancer Policy. 2018 Jun 1;16:73-81.
- Hanson CM, Eckert L, Bloem P, Cernuschi T. Gavi
HPV programs: application to implementation. Vaccines.
- Asempah E. HPV Vaccine and Cervical Cancer Policy
and Policymaking Research Interest in sub-Saharan
Africa: A Scoping Review. Journal of Cancer Policy. 2020
- Binka C, Doku DT, Awusabo-Asare K. Experiences
of cervical cancer patients in rural Ghana: An exploratory
study. PloS One. 2017 Oct 11;12(10):e0185829.
- Nartey Y, Hill PC, Amo-Antwi K, Nyarko KM, Yarney
J, Cox B. Cervical cancer in the Greater Accra and Ashanti
regions of Ghana. Journal of Global Oncology. 2017
- I. IARC, Ghana: Human Papillomavirus and Related
Cancers, Fact Sheet 2019, Fact Sheet. (2018) 2.
- Awua AK, Doe ED. Protocol for a systematic review
of research on HPV and cervical cancer in Ghana, up until
the year 2017: informing research and policy direction on
cervical cancer prevention in Ghana. BMJ Open. 2018 Jul
- Asare M, Agyei-Baffour P, Lanning BA, Barimah Owusu A, Commeh ME, Boozer K, et al. Multi-Theory Model and Predictors of Likelihood of Accepting the Series of HPV
Vaccination: A Cross-Sectional Study among Ghanaian
Adolescents. International Journal of Environmental
Research and Public Health. 2020 Jan;17(2):571.
- Ziba FA, Baffoe P, Dapare PP, Shittu SO, Antuamwine
BB. Awareness and knowledge level of cervical cancer
among women of reproductive age in Bolgatanga
municipality. Journal of Medical and Biomedical Sciences.
- Williams MS, Kenu E, Dzubey I, Dennis-Antwi JA,
Fontaine K. A qualitative study of cervical cancer and
cervical cancer screening awareness among nurses in
Ghana. Health Care for Women International. 2018 May
- Perlman S, Wamai RG, Bain PA, Welty T, Welty E,
Ogembo JG. Knowledge and awareness of HPV vaccine
and acceptability to vaccinate in sub-Saharan Africa: a
systematic review. PloS One. 2014 Mar 11;9(3):e90912.
- WHO, Accelerating the elimination of cervical cancer
as a global public health problem. Report by the Director-
General, (2019). https://apps.who.int/gb/ebwha/pdf_
files/EB146/B146_9-en.pdf (accessed September 26,